Abstract
Serum lactate dehydrogenase (LDH) levels are recognized as an indirect biomarker of tumor hypoxia and angiogenesis for several solid tumors. Ramucirumab represents the first molecularly targeted agent proven to be effective in second-line therapy for advanced gastric or gastro-oesophageal junction adenocarcinoma, alone or in combination with chemotherapy. However, little is known so far about potential predictive factors of benefit from antiangiogenic treatment. Thus, we conducted an observational retrospective study aimed at evaluating the possible differential prognostic impact of baseline serum LDH levels in advanced gastric cancer (GC) patients treated or not with ramucirumab in the second-line setting.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
